Using brain stimulation to reduce opioid relapse
Official title: tDCS to Decrease Opioid Relapse (UH3)
Run by Butler Hospital · NCT06432465 · Data updated 2026-11-12
This study is testing if a brain stimulation technique can help people who are trying to overcome opioid addiction by reducing cravings and preventing relapse while they are on treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 60 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Butler Hospital Academic / other |
| Locations | 1 site (Providence, Rhode Island) |
| Status | Recruiting |
| Started | April 17, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT06432465 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 21-60 who are currently opioid dependent and have recently initiated treatment with buprenorphine or methadone.
✕Probably not a fit
Patients with severe psychiatric disorders, significant neurocognitive dysfunction, or other contraindications to tDCS may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of transcranial direct current stimulation (tDCS) on opioid-dependent individuals who have recently started treatment with buprenorphine or methadone. Participants will be randomly assigned to receive either active tDCS combined with cognitive control network priming or a sham treatment over five sessions. The study aims to assess long-term neurobehavioral outcomes, including rates of opioid relapse and craving, using electroencephalographic (EEG) measurements at multiple time points. The goal is to understand how tDCS can influence brain activity related to craving and cognitive control in this population.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of relapse in patients with opioid use disorder.
How similar studies have gone: Previous studies have shown promise in using brain stimulation techniques for addiction treatment, but this specific approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. current opioid dependence 2. between 21-60 years of age 3. recent initiation of buprenorphine or methadone (≤90 days) 4. enrolled in Butler Hospital's Alcohol and Drug Inpatient Unit, Alcohol and Drug Partial Hospital Treatment Program, Intensive Outpatient Services, or Outpatient Services at Butler Hospital OR receive opioid-treatment services in the community. Exclusion Criteria: 1. current diagnosis of organic brain disorder (e.g., Parkinson's disease, Huntington's disease, multiple sclerosis, intracranial mass/infection, hydrocephalus) 2. bipolar, schizophrenia, schizoaffective, or schizophreniform disorder, or current psychosis associated with any disorder 3. current suicidality 4. evidence of significant neurocognitive dysfunction 5. conditions associated with heightened tDCS risks, e.g., seizure disorder, nonremovable intracranial metal objects (other than dental fillings and dental implants), skin disease or active lesions on the scalp, migraine/other headache disorder with significant active symptoms, traumatic brain injury or skull fracture within the past year, any implanted medical devices or device components that can interact with electromagnetic fields or are controlled by physiological signals 6. probation/parole requirements or an upcoming move that might interfere with protocol participation 7. planning to terminate buprenorphine or methadone in less than 3 months 8. current pregnancy or plan to become pregnant in the next month.
Where it's running
-
Butler Hospital
Providence, Rhode Island, United States Recruiting
Study contacts
- Principal investigator: Abrantes Abrantes, Ph.D. — Butler Hospital
- Study coordinator: Ana M Abrantes, Ph.D.
- Email: ana_abrantes@brown.edu
- Phone: 4014556440
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CBD for Opioid Dependence and Pain on Buprenorphine
This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.
-
Cebranopadol for opioid withdrawal in adults with chronic pain
This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.
-
emPath platform pilot to link and keep adults with opioid use disorder in care in Durham
This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.
-
CB1 Receptors in Opioid Use Disorder Measured with a PET Radioligand
This study tests CB1 receptor availability in people with opioid use disorder starting opioid agonist therapy and compares them with healthy adults.
-
STORC: Training a support person plus patient navigation after birth
We’re testing whether training a designated support person and using patient navigation after delivery helps people with opioid use disorder build recovery resources and stay in treatment.
-
Personalized Addiction Treatment Enhancement for Opioid Use Disorder
A digital platform run by peer recovery supporters will be tested to help adults with opioid use disorder who are on buprenorphine or methadone stay in treatment and improve outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.